Citation
5T4 as a target for immunotherapy in renal cell carcinoma. 2009, 9 (12):1705-9 Expert Rev Anticancer TherJournal
Expert Review of Anticancer TherapyDOI
10.1586/era.09.152PubMed ID
19954280Type
ArticleLanguage
enISSN
1744-8328ae974a485f413a2113503eed53cd6c53
10.1586/era.09.152
Scopus Count
Related articles
- Immunotherapeutic approaches for renal cancer.
- Authors: Pizza G, de Vinci C, Viza D
- Issue date: 2002
- Current immunotherapeutic strategies in renal cell carcinoma.
- Authors: Amato RJ
- Issue date: 2007 Oct
- Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
- Authors: Acres B
- Issue date: 2007 Sep
- Immunotherapy for renal cell cancer.
- Authors: Yang JC, Childs R
- Issue date: 2006 Dec 10
- Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
- Authors: Amato RJ, Shingler W, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R
- Issue date: 2008 Nov 15